期刊
CURRENT ATHEROSCLEROSIS REPORTS
卷 17, 期 4, 页码 -出版社
CURRENT MEDICINE GROUP
DOI: 10.1007/s11883-015-0500-2
关键词
FXR; Obetacholic acid; Bile acid; NAFLD; NASH; Alcoholic hepatitis
资金
- National Institutes of Health (NIH) [K08-AA021424, P30-DK-50306]
- Robert Wood Johnson Foundation [71586]
Non-alcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and a risk factor for both cardiovascular and hepatic related morbidity and mortality. The increasing prevalence of this disease requires novel therapeutic approaches to prevent disease progression. Farnesoid X receptors are bile acid receptors with roles in lipid, glucose, and energy homeostasis. Synthetic farnesoid X receptor (FXR) agonists have been developed to specifically target these receptors for therapeutic use in NAFL D patients. Here, we present a review of bile acid physiology and how agonismof FXR receptors has been examined in preclinical and clinical NAFLD. Early evidence suggests a potential role for synthetic FXR agonists in the management of NAFLD; however, additional studies are needed to clarify their effects on lipid and glucose parameters in humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据